LSP, Andera et al. invest €116m in AM-Pharma

Existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare also took part in the round.

Proceeds will be used for the 1,400-patient international pivotal phase-III trial of recombinant human alkaline phosphatase (recAP) in patients with sepsis-associated acute kidney injury (AKI).

The company is backed by venture capital funds and corporate venture funds, and has raised €195m in equity and debt to date, according to a statement.

Previous funding
AM-Pharma completed a first financing round in 2001, gathering a total of €640,000 from management, private investors and BioPartner Startup Ventures, a venture fund supported by the Dutch Ministry of Economic Affairs.

Inventages and ABN Amro Life Sciences Capital provided AM-Pharma with €6m and €3m respectively in 2005. Two years later, Forbion and Inventages contributed €2.5m to the biotech and in 2008 injected €7m. At the time, AM-Pharma was making preparations for a potential IPO, and Forbion owned a large minority stake in the company, Unquote previously reported.

It then raised €29.2m from Ysios, KLS, BB Biotech, Forbion, Idinvest and Inventages in 2011. Ysios and KLS led the round, with the former contributing €4.5m in capital.

Three years later, Gilde and existing investors injected a further €12.2m funding.

Company
AM-Pharma is a clinical stage biopharmaceutical company developing treatment for AKI with its drug recAP. AKI has a high mortality rate and no approved pharmacological treatments. The most prominent cause of AKI, which affects millions of patients worldwide, is sepsis.

Founded in 2001, the business is based in Bunnik.

People
AM-Pharma – Erik van den Berg (CEO).  
LSP – Martijn Kleijwegt (managing partner).
Andera Partners – Raphaël Wisniewski (partner).  

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Benelux
• Healthcare
• Netherlands
• Life Science Partners
• Andera Partners